These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 32012718)

  • 1. Toll-like Receptors from the Perspective of Cancer Treatment.
    Javaid N; Choi S
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis.
    Khajeh Alizadeh Attar M; Anwar MA; Eskian M; Keshavarz-Fathi M; Choi S; Rezaei N
    Med Res Rev; 2018 Sep; 38(5):1469-1484. PubMed ID: 29283184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting pattern-recognition receptors to discover new small molecule immune modulators.
    Zhu G; Xu Y; Cen X; Nandakumar KS; Liu S; Cheng K
    Eur J Med Chem; 2018 Jan; 144():82-92. PubMed ID: 29268133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
    Arsenault RJ; Kogut MH; He H
    Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.
    O'Neill LA; Bryant CE; Doyle SL
    Pharmacol Rev; 2009 Jun; 61(2):177-97. PubMed ID: 19474110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells.
    Mäkelä SM; Strengell M; Pietilä TE; Osterlund P; Julkunen I
    J Leukoc Biol; 2009 Apr; 85(4):664-72. PubMed ID: 19164128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-Like Receptors Signaling in the Tumor Microenvironment.
    McCall KD; Muccioli M; Benencia F
    Adv Exp Med Biol; 2020; 1223():81-97. PubMed ID: 32030686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.
    Li TT; Ogino S; Qian ZR
    World J Gastroenterol; 2014 Dec; 20(47):17699-708. PubMed ID: 25548469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Toll-Like Receptors in Hematopoietic Malignancies.
    Monlish DA; Bhatt ST; Schuettpelz LG
    Front Immunol; 2016; 7():390. PubMed ID: 27733853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptors in the pathogenesis of neuroinflammation.
    Kumar V
    J Neuroimmunol; 2019 Jul; 332():16-30. PubMed ID: 30928868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatases in toll-like receptors signaling: the unfairly-forgotten.
    Lannoy V; Côté-Biron A; Asselin C; Rivard N
    Cell Commun Signal; 2021 Jan; 19(1):10. PubMed ID: 33494775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quercetin modulates toll-like receptor-mediated protein kinase signaling pathways in oxLDL-challenged human PBMCs and regulates TLR-activated atherosclerotic inflammation in hypercholesterolemic rats.
    Bhaskar S; Helen A
    Mol Cell Biochem; 2016 Dec; 423(1-2):53-65. PubMed ID: 27665434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR2 stimulation impairs anti-inflammatory activity of M2-like macrophages, generating a chimeric M1/M2 phenotype.
    Quero L; Hanser E; Manigold T; Tiaden AN; Kyburz D
    Arthritis Res Ther; 2017 Nov; 19(1):245. PubMed ID: 29096690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptors and adaptor molecules in liver disease: update.
    Seki E; Brenner DA
    Hepatology; 2008 Jul; 48(1):322-35. PubMed ID: 18506843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.
    Fitzgerald KA; Palsson-McDermott EM; Bowie AG; Jefferies CA; Mansell AS; Brady G; Brint E; Dunne A; Gray P; Harte MT; McMurray D; Smith DE; Sims JE; Bird TA; O'Neill LA
    Nature; 2001 Sep; 413(6851):78-83. PubMed ID: 11544529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptors and cutaneous melanoma.
    Coati I; Miotto S; Zanetti I; Alaibac M
    Oncol Lett; 2016 Nov; 12(5):3655-3661. PubMed ID: 27900049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collaborative action of Toll-like and NOD-like receptors as modulators of the inflammatory response to pathogenic bacteria.
    Oviedo-Boyso J; Bravo-Patiño A; Baizabal-Aguirre VM
    Mediators Inflamm; 2014; 2014():432785. PubMed ID: 25525300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression.
    Giurini EF; Madonna MB; Zloza A; Gupta KH
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor ligands directly promote activated CD4+ T cell survival.
    Gelman AE; Zhang J; Choi Y; Turka LA
    J Immunol; 2004 May; 172(10):6065-73. PubMed ID: 15128790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.